Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it ...

Newco ALTx Therapeutics Ltd. has launched with a £12.55 million (US$17.1 million) seed round to develop inhibitors of the alternative lengthening of telomeres (ALT) pathway, by which 10% to 15% of ...

The U.K.’s main research funding agency is looking to put more public money into proof of concept and pre-seed funding of ...

Despite reporting strong fourth-quarter (Q4) organic sales growth of $5.29 billion, up 12.7% year-on-year, Boston Scientific ...

Prelude Therapeutics Inc. has received IND clearance from the FDA for PRT-12396, a mutant-selective JAK2 V617F inhibitor ...

Amgen Inc. said as part of its quarterly results that the company has turned down a request from the U.S. FDA that Tavneos (avacopan) be taken off the market. The complement 5a receptor antagonist was ...

In a one-two-punch to pharmacy benefit managers (PBMs), the U.S. FTC announced Feb. 4 what it’s calling a “landmark settlement” with the Cigna Group’s Express Scripts Inc. and its affiliates that will ...

ABL Bio Inc. has submitted an IND application to the FDA seeking clearance to begin a phase I trial of ABL-209 (NEOK-002).

Looking to fill a treatment gap, the U.S. Biomedical Advanced Research and Development Authority (BARDA) is launching the first stage of a $100 million prize competition to support development of ...

Zipbio has signed an exclusive license agreement with Meiragtx Holdings plc to advance an AAV gene therapy for geographic atrophy. Under the agreement, Meiragtx will receive exclusive rights to Zipbio ...

IL-10-based approaches have shown promise in cancer immunotherapy by activating exhausted CD8+ T cells, but severe hematological toxicities have limited their clinical use. Recent strategies aim to ...

Acute ischemic stroke still represents a public health challenge due to its high incidence and mortality rate. Current treatments may effectively restore the blood flow, but recanalization by opening ...